Inhibidores del cotransporte de sodio glucosa (SGLT2). Una nueva clase de antidiabéticos orales
DOI:
https://doi.org/10.47196/diab.v48i3.189Palabras clave:
inhibidores, drogas antidiabéticasResumen
El Comité de Nefropatía de la Sociedad Argentina de Diabetes el 14 de diciembre de 2013 realizó su Jornada Anual donde se revisó el tema “Inhibidores del cotransporte de sodio glucosa 2, gliflozinas, una nueva clase de drogas antidiabéticas orales”.
Esta nueva clase de antidiabéticos orales tiene la particularidad de no actuar a través de la insulina. El mecanismo de la inhibición es independiente de los niveles de insulina circulante o de la sensibilidad de la misma.
Citas
Nair S, Wilding J. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab. 2010; 95: 34-42.
Lee Y, Han H. Regulatory mechanisms of Na/glucose cotransporters in renal proximal tubule cells. Kidney Int. 2007; 72: S27-S35.
Jabbour S, Goldstein B. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 2008 Aug; 62: (8), 1279-1284.
Wright E. Renal Na (+)-glucose cotransporters. Am. J. Physiol. Renal Physiol. 2001; 280: F10-F18.
Abdul-Ghani M, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr. Diab. Rep. 2012 12:230-238.
DeFronzo RA, Davidson J, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012 Jan; 14(1): 5-14.
Wright E. Active sugar transport in health and disease. J. Intern. Med. 2007; 261:32-43
Neumiller J. Sodium-glucose co-transport inhibitors. Drugs 2010;70(4):377-385.
Basile J. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. Postgraduate Med. 2011;123(4):38-45.
Gerich J. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24:382-391.
Burton D, Theodore W. Post túbulo proximal. En: Rose & Post Trastornos de los electrolitos y del equilibrio ácido-base. USA: Marbán Libros, S.L. 2005: 71-111.
DeFronzo RA. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, Obes. Metab. 2011; 14: 5-14.
Colin H. Development and potential role of type 2 sodium-glucose transporter inhibitors for management of type 2. Diabetes. Diab. Ther. 2011;2(3):133-145.
Nair S, Wilding J. Sodium glucose cotransporter 2 inhibitors as a new treatment for Diabetes Mellitus. J. Clin. Endocrinol. Metab. 2010:95:34-42.
Kim Y. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes, Met. Syndr. and Obes. 2012; 5:313-327.
DeFronzo RA. Efficacy and Safety of SGLT2 inhibitors in the treatment of type 2 Diabetes Mellitus. Curr. Diab. Rep. 2012; 12: 230-238.
Boldys A. Inhibitors of type 2 sodium glucose cotransporters- a new strategy for diabetes treatment. Pharmacological Reports 2009; 61:778-784.
Chao E, Henry R. SGLT2 inhibition, a novel strategy for diabetes treatment. Nature Reviews 2010; 9:551-559.
DeFronzo RA, et al. The role of the kidney in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012;14:5-14.
List JF, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care: 2009; 32:650-657.
Dapagliflozin. Forxiga® Approved product information. Bristol-Myers Squibb. Feb 2013.
Canagliflozin. Invokana® Product information. Janssen-Cilag. Sep 2013.
Cefalu WT, et al. Efficacy and safety of canagliflozin vs glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): Lancet 2013; 382:941-50.
Stenlof K, et al. Efficacy and safety of canagliflozin monotherapy in subjets with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 2013; 15:372-382.
Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology: 2013;65: 317-327.
Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther.: 2009;85:513-19.
Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33:2217-24.
List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7.
Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33.
Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern. Med. 2012; 156:405-15
Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind placebo-controlled trial. Diabetes, Obesity and Metabolism 2011; Vol. 13, N° 10: 928-938.
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non inferiority trial. Diabetes Care 2011; 34:2015-22.
Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAd visoryCommittee/UCM262996.pdf.
Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013; 36(5):1260-5
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/ 002322/WC500136024.pdf.
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes, Obesity and Metabolism: 2012; 14: 5-14.
Bailey CJ. Where do SGLT2 inhibitors fit in diabetes care? New class of drugs turns glucosuria on its head. Medscape Diabetes & Endocrinology: 2013; October 15.
Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter 2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism: 2013; 15: 392-402.
Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr. Diab. Rep. 2012; 12: 230-238.
Andrianesis V, Doupis J. The role of kidney in glucose homeostasis. SGLT2 inhibitors, a new approach in diabetes treatment. Expert Rev. Clin. Pharmacol. 2013; 6 (5): 519-539.
Aschner PJ. Canaglifozin for the treatment of adults with type 2 diabetes. Diabetes Manage: 2013; 3 (4): 343-350.
Kim Y, Babu A. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab. Syndr. and Obesity: targets and therapy 2012:5 313-327.
List J, Woo V, Morales E, Tang W, Fiedorek F. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32:650-657.
Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity and Metabolism 2012; 14: 539-545.
Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocr. Metab. 2012; 97: 1020-1031.
Bailey C, Gross J, Pieters A, Bastien A, List J. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
Wilding J, Norwood P, T’Joen C, Bastien A, List J, Fiedorek F. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Diabetes Care 2009; 32: 1656-1662.
Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes. Metab. 2010; 12:510-516.
Rosenstock J, Vico M, Wei L, Salsali A, List J. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk inpatients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
Ferrannini E, Ramos S, Salsali A, Tang W, List J. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care 2010; 33: 2217-2224.
Clar C, Gill Ja Court. Systematic review of SGLT2 inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012:2 e001007.doi10./bmj open-2012-001007.
Chao E, Henry R. SGLT2 inhibition a novel strategy for diabetes treatment Nature Review Drug Discovery: 2010;9:551-557.
Rosentock and the Canagliflozin Dia 2001 Study Group. Dose rangin effects of canagliflozin a sodium glucose contransporter 2 inhibitor as add on to metformin in subject with type 2 diabetes. Diabetes Care: 2012; 35:1232-1238.
List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-7.
http://www.fda.gov/.../AdvisoryCommittees/CommitteesMeetingMaterials/.../EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262990.pdf. FDA briefing document. NDA 202293.
Taharani Abd, Barnett A, Bailey C. SGLT2 inhibitors in management of diabetes. The Lancet Endocrinology and Metabolism 2013:1:140-51.no figura en el texto
Nauck M, Del Prato S, Rohwedder K, Elze M, Parikh S. Dapagliflozin vs. glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised, controlled trial. Diabetologia 2010; 53(Suppl. 1): S1-S556.
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidney in glucose homeostasisia new path towards normalizing glycemia. Diabetes, Obesity and Metabolism:2012:14:5-14.
Leiter L. Simposium of safety and adverse effects. The role of SGLT2 inhibitors in the treatment of type 2 diabetes. Conferencia dictada en el 74th Congress American Diabetes Association, junio 2014. San Francisco, California. Resúmenes del 74th Congreso de la Asociación Americana de Diabetes 2014.
Goodman & Gilman's. The pharmacological basis of therapeutics. 12th Edition. Section I. General Principles. Chapter 4. Drug toxicity and poisoning. The McGraw-Hill Edition. 2011. Online.
Kasichayanula S, Liu X, Shyu WC, Chang W, Pfister M, Griffen SC, Li T, Lacreta FP, Boulton DW. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes, Obesity and Metabolism 2011; 13: 47-54.
Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, Lacreta FP, Boulton DW. Lack of pharmacokinetic interaction between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv. Ther. 2012; 29 (2): 163-177
Kasichayanula S, Liu X, Lacreta FP, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co- transporter type 2. Clin Pharmacokinet. DOI 10.1007/s40262-013-0104-3. Pushished online: 09 October 2013.
Forxiga: Summary of Product Characteristics. AstraZeneca and Bristol-Myers Squibb.http://www.ema.europa.eu/docs/en_GB/.
Kasichayanula S, Liu X, Lacreta FP, Griffen SC, Boulton DW. Research letter: effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes, Obesity and Metabolism 2013; 15: 280-283.
Pérez López G, González Albrarrán O, Cano Megías M. Inhibidores del cotransporte sodio-glucosa tipo 2 (SGLT2): de la glucosuria renal familiar al tratamiento de la diabetes mellitus tipo 2. Nefrología: 2010; 30(6): 618-25.
DeFronzo RA, Davidson J, Del Prato J. The role of the kidney in the glucose homeostasis a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012; 14:5-14.
http://ec.europa.eu/health/documents/community-register/2012/20121112124487/
anx_124487_es.pdf .
Tahara A, Kurosaki E, Yokono M, Yamajuku M, Kihara, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Schmiedeberg N. Arch. Pharmacol. 2012; 385:423-436.
Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012; 14: 601-607.
Fujimori Y, Katsuno K, Ojima K, Nakashima I, S Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M. European Journal of Pharmacology: 2009; 609:148-154.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
